Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors
Manan Patel1, Kevin Van der Jeught2, Jashodeep Datta3
1Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Despite progress in immunotherapy, many solid tumors remain resistant to T-cell-centric approaches. Mounting evidence implicates myeloid cells as critical drivers of immune evasion, therapeutic resistance, and disease progression. This review surveys the biology of myeloid immunosuppression and highlights translational strategies to target their recruitment, checkpoints, metabolic axes, and suppressive signaling. Together, these efforts underscore the therapeutic promise of integrating myeloid-directed interventions into rational, multimodal cancer immunotherapy.
Despite progress in immunotherapy, many solid tumors remain resistant to T-cell-centric approaches. Mounting evidence implicates myeloid cells as critical drivers of immune evasion, therapeutic resistance, and disease progression. This review surveys the biology of myeloid immunosuppression and highlights translational strategies to target their recruitment, checkpoints, metabolic axes, and suppressive signaling. Together, these efforts underscore the therapeutic promise of integrating myeloid-directed interventions into rational, multimodal cancer immunotherapy.
